PL3844147T3 - Związki chemiczne - Google Patents

Związki chemiczne

Info

Publication number
PL3844147T3
PL3844147T3 PL20816376.6T PL20816376T PL3844147T3 PL 3844147 T3 PL3844147 T3 PL 3844147T3 PL 20816376 T PL20816376 T PL 20816376T PL 3844147 T3 PL3844147 T3 PL 3844147T3
Authority
PL
Poland
Prior art keywords
chemical compounds
compounds
chemical
Prior art date
Application number
PL20816376.6T
Other languages
English (en)
Inventor
Peter RANDS
George Knight
Richard Chubb
Derek Londesbrough
Tiffanie BENWAY
Zelah JOEL
Original Assignee
Small Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1916210.6A external-priority patent/GB201916210D0/en
Priority claimed from GBGB1917320.2A external-priority patent/GB201917320D0/en
Priority claimed from GB2008303.6A external-priority patent/GB2585978B/en
Application filed by Small Pharma Ltd filed Critical Small Pharma Ltd
Publication of PL3844147T3 publication Critical patent/PL3844147T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL20816376.6T 2019-11-07 2020-11-09 Związki chemiczne PL3844147T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1916210.6A GB201916210D0 (en) 2019-11-07 2019-11-07 High purity tryptamines and methods of synthesis thereof
GBGB1917320.2A GB201917320D0 (en) 2019-11-28 2019-11-28 Novel compounds
GB2008303.6A GB2585978B (en) 2019-06-03 2020-06-02 Therapeutic compositions
PCT/EP2020/081502 WO2021089872A1 (en) 2019-11-07 2020-11-09 Compounds

Publications (1)

Publication Number Publication Date
PL3844147T3 true PL3844147T3 (pl) 2022-07-18

Family

ID=75849570

Family Applications (2)

Application Number Title Priority Date Filing Date
PL20816375.8T PL3873883T3 (pl) 2019-11-07 2020-11-09 Sposób syntezy
PL20816376.6T PL3844147T3 (pl) 2019-11-07 2020-11-09 Związki chemiczne

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL20816375.8T PL3873883T3 (pl) 2019-11-07 2020-11-09 Sposób syntezy

Country Status (18)

Country Link
US (6) US11643390B2 (pl)
EP (3) EP3873883B1 (pl)
JP (3) JP7422473B2 (pl)
KR (2) KR20220082092A (pl)
CN (2) CN114829341B (pl)
AU (2) AU2020378647B2 (pl)
BR (1) BR112022008919A2 (pl)
CA (2) CA3160334C (pl)
DK (1) DK3844147T3 (pl)
ES (2) ES2940811T3 (pl)
HR (2) HRP20220797T1 (pl)
HU (2) HUE059403T2 (pl)
IL (2) IL292754B2 (pl)
MX (1) MX2022005399A (pl)
NZ (1) NZ788543A (pl)
PL (2) PL3873883T3 (pl)
PT (2) PT3873883T (pl)
WO (2) WO2021089873A1 (pl)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
NZ788543A (en) * 2019-11-07 2022-10-28 Small Pharma Ltd Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
IL295371A (en) 2020-02-04 2022-10-01 Mindset Pharma Inc Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
US11332441B2 (en) * 2020-03-23 2022-05-17 Caamtech, Inc. Crystalline N-methyl tryptamine derivatives
US11759452B2 (en) 2020-05-08 2023-09-19 Psilera Inc. Compositions of matter and pharmaceutical compositions
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
ES2928395T3 (es) * 2020-06-02 2022-11-17 Small Pharma Ltd Composiciones terapéuticas que comprenden compuestos de N,N-dimetiltriptamina deuteratados o parcialmente deuteratados
EP3902541B1 (en) * 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
WO2021250435A1 (en) 2020-06-12 2021-12-16 Beckley Psytech Limited Pharmaceutical composition comprising 5-methoxy-n,n-dimethyltryptamine
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
EP4155306A1 (en) 2021-01-15 2023-03-29 Beckley Psytech Limited Neuroactive ergoline analogue
WO2022153268A1 (en) 2021-01-15 2022-07-21 Beckley Psytech Limited Tryptamine analogues
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US12378194B2 (en) 2021-05-25 2025-08-05 Atai Therapeutics, Inc. N, n-dimethyltryptamine salts and crystalline salt forms
WO2022261383A1 (en) 2021-06-09 2022-12-15 ATAI Life Sciences AG Novel prodrugs and conjugates of dimethyltryptamine
EP4122916A1 (en) * 2021-07-22 2023-01-25 GH Research Ireland Limited Method for preparing an organic compound
IL310296A (en) * 2021-07-22 2024-03-01 Gh Res Ireland Limited A method for the preparation of a tryptamine derivative
US11697638B2 (en) * 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
EP4159192A1 (en) 2021-09-30 2023-04-05 Biomind Labs Inc Dimethyltriptamine-based nasal spray for the personalised treatment of neurological and psychiatric disorders
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations
IL312859A (en) 2021-11-18 2024-07-01 Cybin Uk Ltd Injectable and inhalable formulations
WO2023108174A1 (en) * 2021-12-10 2023-06-15 Terran Biosciences, Inc. Analogs of 6-methoxy- n, n-dimethyltryptamine
US12012381B2 (en) 2021-12-30 2024-06-18 Atai Therapeutics, Inc. Dimethyltryptamine analogues as nitric oxide delivery drugs
WO2023147423A1 (en) * 2022-01-28 2023-08-03 Miralogx Llc Anxiolytic compounds, pharmaceutical compositions, and methods of treating anxiety and other disorders
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
US20230346718A1 (en) * 2022-04-27 2023-11-02 Yale University Method of treating, ameliorating and/or preventing depression
GB202212116D0 (en) 2022-08-19 2022-10-05 Beckley Psytech Ltd Pharmaceutically acceptable salts and Compositions thereof
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024079314A1 (en) 2022-10-13 2024-04-18 Cybin Uk Ltd Method of administration of a parenteral formulation comprising a psychedelic agent
WO2024108195A1 (en) 2022-11-17 2024-05-23 Remedi, Inc. Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
TW202430149A (zh) * 2022-12-01 2024-08-01 美商雅特益醫療公司 N,n-二甲基色胺之結晶形式及其使用方法
WO2024156713A1 (en) 2023-01-23 2024-08-02 Cybin Uk Ltd Treatment of psychiatric or neurological disorders by parenteral administration of a single, effective parenteral dose of a short-acting psychedelic agent
AU2024242138A1 (en) 2023-03-31 2025-11-13 Cybin Uk Ltd Combination comprising a monoamine antidepressant agent and a short-duration psychedelic agent
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
US12129234B1 (en) * 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12180158B1 (en) * 2023-08-03 2024-12-31 Gilgamesh Pharmaceuticals, Inc. Crystalline fumarate salts of n-ethyl-2-(5-fluoro-1H-indol-3-yl)-n-methylethan-1-amine
WO2026013174A1 (en) 2024-07-10 2026-01-15 Cybin Uk Ltd Pharmaceutical compositions comprising deuterated n,n-dimethyltryptamine

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4336378A (en) 1980-04-10 1982-06-22 Sandoz, Inc. Isoxazolyl indolamines
PT100603A (pt) * 1991-06-21 1993-08-31 Smithkline Beecham Plc Uso de analogos de triptamina, analogos de triptamina, sua preparacao e composicoes farmaceuticas que os contem
US6376531B1 (en) 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
EP2036540A3 (en) 2000-06-16 2009-12-16 Jagotec AG Improved injectable dispersions of propofol
WO2004085392A1 (en) 2003-03-25 2004-10-07 Faust Pharmaceuticals Melatonin derivatives and their use for treating neurological dysfunctions
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
WO2008071455A1 (en) 2006-12-15 2008-06-19 Bayer Schering Pharma Aktiengesellschaft Bicyclic acyltryptophanols
CZ302424B6 (cs) * 2007-06-13 2011-05-11 Zentiva, A. S. Zpusob prípravy almotriptanu o vysoké cistote
SG183696A1 (en) * 2007-08-06 2012-09-27 Biotie Therapies Inc Medicaments comprising nepicastat for use in treating dependence on a substance
US20090076121A1 (en) 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched sumatriptan
EP2209380A4 (en) 2007-10-09 2011-09-14 Mark T Hamann METHOD OF USE OF COMPOSITIONS WITH ANTIDEPRESSIVE EFFICACY, MOOD EFFICACY AND OTHER NEUROLOGICAL EFFECTIVENESS AND COMPOSITIONS THEREOF
US20100113496A1 (en) * 2008-09-25 2010-05-06 Auspex Pharmaceuticals, Inc. Piperidine modulators of vmat2
WO2013063492A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
EP2897615A4 (en) * 2012-09-18 2016-04-27 Auspex Pharmaceuticals Inc PHARMACOKINETIC FORMULATIONS OF DEUTERATED BENZOCHINOL INHIBITORS OF THE VESICLE MONOAMINE TRANSPORTER 2
CN108299400B (zh) * 2013-03-14 2021-02-19 达特神经科学(开曼)有限公司 作为pde4抑制剂的取代的吡啶和取代的吡嗪化合物
JP2017527614A (ja) * 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
US10336703B2 (en) * 2015-05-12 2019-07-02 Council Of Scientific And Industrial Research Process for the synthesis of ivacaftor and related compounds
US12343337B2 (en) 2016-09-29 2025-07-01 The Regents Of The University Of California Compounds for increasing neural plasticity
CN110740728A (zh) 2017-02-09 2020-01-31 卡马技术有限责任公司 包含裸头草碱衍生物的组合物和方法
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US11723894B2 (en) * 2017-10-26 2023-08-15 Terran Biosciences, Inc. Combination product for the treatment of neurological and/or psychiatric disorders
WO2019089902A1 (en) 2017-11-01 2019-05-09 Drexel University Compounds, compositions, and methods for treating diseases
SI4349407T1 (sl) 2019-02-22 2025-06-30 GH Research Ireland Limited 5-metoksi-n,n-dimetiltriptamin (5-meo-dmt) za zdravljenje velike depresivne motnje
EA202192319A1 (ru) 2019-02-22 2021-12-21 Гх Рисерч Айрленд Лимитед Композиции, содержащие 5-метокси-n,n-диметилтриптамин (5-meo-dmt) для применения в лечении психических расстройств
BR112021016620A2 (pt) 2019-02-27 2021-11-03 Univ California Azepino-indóis e outros heterociclos para o tratamento de distúrbios cerebrais
CN113840600B (zh) * 2019-02-27 2026-02-13 加利福尼亚大学董事会 用于治疗脑疾病的n-取代吲哚和其他杂环化合物
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
NZ788543A (en) 2019-11-07 2022-10-28 Small Pharma Ltd Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
CN111072492A (zh) * 2019-11-29 2020-04-28 浙江工业大学 一种合成3,4-二氯-2-氨基-5-氟联苯的方法
IL295371A (en) 2020-02-04 2022-10-01 Mindset Pharma Inc Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
WO2021234608A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
JP7766623B2 (ja) 2020-05-19 2025-11-10 サイビン アイアールエル リミテッド 重水素化トリプタミン誘導体および使用方法
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
US12042564B2 (en) 2020-06-02 2024-07-23 Cybin Uk Ltd Therapeutic solid dosage forms
US11773062B2 (en) 2021-03-22 2023-10-03 Small Pharma Ltd Deuterated compounds
GB202008961D0 (en) 2020-06-12 2020-07-29 Beckley Psytech Ltd Pharmaceutical composition
CN116056705A (zh) 2020-08-05 2023-05-02 巴塞尔大学医院 用于dmt辅助心理疗法的静脉内dmt施用方法
AU2021334933B2 (en) 2020-08-28 2023-01-19 Cybin Uk Ltd Injectable formulation
US11406619B2 (en) 2020-08-28 2022-08-09 Small Pharma Ltd Injectable formulations
US20220062237A1 (en) 2020-08-28 2022-03-03 Small Pharma Ltd Injectable formulation
US20230355583A1 (en) 2020-10-02 2023-11-09 Cybin Irl Limited Methods for delivery of psychedelic medications by inhalation and systems for performing the methods
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof
US12521370B2 (en) 2020-12-01 2026-01-13 Cybin Uk Ltd Inhalable formulations
US11660289B2 (en) 2020-12-01 2023-05-30 Small Pharma Ltd. Deuterated or partially deuterated N,N-dimethyltryptamine compounds
EP4255421A1 (en) 2020-12-01 2023-10-11 Small Pharma Ltd Inhalable formulations
AU2021391581A1 (en) 2020-12-01 2023-07-06 Cybin Uk Ltd Deuterated or partially deuterated n,n-dimethyltryptamine compounds
US11697638B2 (en) 2021-09-08 2023-07-11 Small Pharma Ltd 5-methoxy-N,N-dimethyltryptamine crystalline forms
US12318477B2 (en) 2021-11-18 2025-06-03 Cybin Uk Ltd Injectable and inhalable formulations

Also Published As

Publication number Publication date
IL292754A (en) 2022-07-01
IL292754B1 (en) 2025-08-01
CN114829340A (zh) 2022-07-29
US20230167056A1 (en) 2023-06-01
CN114829340B (zh) 2023-12-12
PT3844147T (pt) 2022-07-04
US11643390B2 (en) 2023-05-09
IL292753A (en) 2022-07-01
PL3873883T3 (pl) 2023-05-08
CN114829341A (zh) 2022-07-29
CA3160334A1 (en) 2021-05-14
EP3844147B1 (en) 2022-04-06
CA3160337A1 (en) 2021-05-14
HUE061482T2 (hu) 2023-07-28
HRP20230281T1 (hr) 2023-04-28
BR112022008919A2 (pt) 2022-08-09
WO2021089873A1 (en) 2021-05-14
AU2020378647A1 (en) 2022-06-09
IL292753B2 (en) 2024-01-01
ES2920681T3 (es) 2022-08-08
HRP20220797T1 (hr) 2022-10-14
CN114829341B (zh) 2024-03-08
JP7422473B2 (ja) 2024-01-26
CA3160334C (en) 2024-04-30
IL292753B1 (en) 2023-09-01
US11578039B2 (en) 2023-02-14
KR20230142817A (ko) 2023-10-11
WO2021089872A1 (en) 2021-05-14
AU2020378647B2 (en) 2023-06-15
US20220281818A1 (en) 2022-09-08
EP3873883A1 (en) 2021-09-08
US12157723B2 (en) 2024-12-03
MX2022005399A (es) 2022-07-05
US20210395201A1 (en) 2021-12-23
PT3873883T (pt) 2023-03-24
KR20220082092A (ko) 2022-06-16
DK3844147T3 (da) 2022-07-04
AU2020381103A1 (en) 2022-06-09
EP4180037A1 (en) 2023-05-17
US20230250059A1 (en) 2023-08-10
IL292754B2 (en) 2025-12-01
NZ788543A (en) 2022-10-28
US20240217929A1 (en) 2024-07-04
JP7423131B2 (ja) 2024-01-29
JP7748437B2 (ja) 2025-10-02
JP2023500532A (ja) 2023-01-06
CA3160337C (en) 2023-08-29
US12084417B2 (en) 2024-09-10
ES2940811T3 (es) 2023-05-11
EP3873883B1 (en) 2022-12-21
US20250042852A1 (en) 2025-02-06
JP2022546635A (ja) 2022-11-04
EP3844147A1 (en) 2021-07-07
AU2020381103B2 (en) 2022-08-11
HUE059403T2 (hu) 2022-11-28
JP2024028798A (ja) 2024-03-05

Similar Documents

Publication Publication Date Title
PL3844147T3 (pl) Związki chemiczne
IL286833A (en) Compositions containing brazzein
IL283692A (en) Novel composition
DK4165024T3 (da) Cyclobutyldihydroquinolinsulfonamid-forbindelser
DK3956033T3 (da) Bicykliske forbindelser
DK3692040T3 (da) Kemiske forbindelser
LT3810602T (lt) Junginiai
EP4129997A4 (en) Octahydropyrazinodiazanaphthyridine dione compounds
DK3768271T3 (da) Organiske forbindelser
DK4083038T3 (da) Pyridazinylthiazolcarboxamidforbindelse
EP4149556C0 (en) PEG LIPIDOIDS COMPOUNDS
DK4320112T3 (da) Pyridinylsubstituerede oxoisoindolinforbindelser
IL310528A (en) Pyrazolopyridinone compounds
IL288608A (en) Etching compositions
EP3790384A4 (en) STABILIZED CHEMICAL COMPOSITION
DK3762378T3 (da) Herbicide forbindelser
IL291119A (en) Etching composition
HUE065134T2 (hu) Vegyületek
EP4143199C0 (en) NUCLEOTIDE PROMEDICINAL COMPOUNDS
LT3867247T (lt) Naujieji junginiai
IL287919A (en) Chemical process
DK3808747T3 (da) Imidazopyridinon-forbindelse
IL287656A (en) Etching compositions
IL288684A (en) Etching compositions
HUE056928T2 (hu) Új vegyületek